Research ArticleOriginal Article

The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility

Fengjiao Jin, Zhaozhen Wu, Xiao Hu, Jiahui Zhang, Zihe Gao, Xiao Han, Junfang Qin, Chen Li and Yue Wang
Cancer Biology & Medicine February 2019, 16 (1) 38-54; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0253

References

  1. 1.↵
    2. Ferlay J,
    3. Soerjomataram I,
    4. Dikshit R,
    5. Eser S,
    6. Mathers C,
    7. Rebelo M, et al.
    Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int J Cancer. 2015; 136: E359–86.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Donovan GR,
    3. Baldo BA,
    4. Sutherland S.
    Molecular cloning and characterization of a major allergen (myr p i) from the venom of the australian jumper ant, myrmecia pilosula. Biochim Biophys Acta. 1993; 1171: 272–80.
    OpenUrlPubMed
  3. 3.↵
    2. McCubrey JA,
    3. Davis NM,
    4. Abrams SL,
    5. Montalto G,
    6. Cervello M,
    7. Basecke J, et al.
    Diverse roles of gsk-3: Tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul. 2014; 54: 176–96.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Sutherland C.
    What are the bona fide gsk3 substrates? Int J Alzheimers Dis. 2011; 2011: 505607.
    OpenUrl
  5. 5.
    2. Fang X,
    3. Yu SX,
    4. Lu Y,
    5. Bast RC Jr..,
    6. Woodgett JR,
    7. Mills GB.
    Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase a. Proc Natl Acad Sci U S A. 2000; 97: 11960–5.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Tejeda-Munoz N,
    3. Gonzalez-Aguilar H,
    4. Santoyo-Ramos P,
    5. Castaneda-Patlan MC,
    6. Robles-Flores M.
    Glycogen synthase kinase 3beta is positively regulated by protein kinase czeta-mediated phosphorylation induced by wnt agonists. Mol Cell Biol. 2015; 36: 731–41.
    OpenUrl
  7. 7.↵
    2. McCubrey JA,
    3. Steelman LS,
    4. Bertrand FE,
    5. Davis NM,
    6. Sokolosky M,
    7. Abrams SL, et al.
    Gsk-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014; 5: 2881–911.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Cole A,
    3. Frame S,
    4. Cohen P.
    Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (gsk3) in mammalian cells is an autophosphorylation event. Biochem J. 2004; 377: 249–55.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Medina M,
    3. Wandosell F.
    Deconstructing gsk-3: The fine regulation of its activity. Int J Alzheimers Dis. 2011; 2011: 479249.
    OpenUrl
  10. 10.↵
    2. Martelli AM,
    3. Buontempo F,
    4. Evangelisti C.
    Gsk-3beta: A key regulator of breast cancer drug resistance. Cell Cycle. 2014; 13: 697–8.
    OpenUrl
  11. 11.↵
    2. Shao J,
    3. Teng Y,
    4. Padia R,
    5. Hong S,
    6. Noh H,
    7. Xie X, et al.
    Cop1 and gsk3beta cooperate to promote c-jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia. 2013; 15: 1075–85.
    OpenUrlCrossRefPubMed
  12. 12.
    2. Zhai L,
    3. Ma C,
    4. Li W,
    5. Yang S,
    6. Liu Z.
    Mir-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of erk5. Mol Carcinog. 2016; 55: 1990–2000.
    OpenUrl
  13. 13.
    2. Zeng J,
    3. Liu D,
    4. Qiu Z,
    5. Huang Y,
    6. Chen B,
    7. Wang L, et al.
    Gsk3beta overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS One. 2014; 9: e9123.
  14. 14.
    2. Zhang ZJ,
    3. Yang YK,
    4. Wu WZ.
    Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice. J Transl Med. 2014; 12: 57.
    OpenUrl
  15. 15.↵
    2. Domoto T,
    3. Pyko IV,
    4. Furuta T,
    5. Miyashita K,
    6. Uehara M,
    7. Shimasaki T, et al.
    Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016; 107: 1363–72.
    OpenUrlCrossRef
  16. 16.↵
    2. Sokolosky M,
    3. Chappell WH,
    4. Stadelman K,
    5. Abrams SL,
    6. Davis NM,
    7. Steelman LS, et al.
    Inhibition of gsk-3beta activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in mcf-7 breast cancer cells. Cell Cycle. 2014; 13: 820–33.
    OpenUrl
  17. 17.↵
    2. Zhang D,
    3. Fei F,
    4. Li S,
    5. Zhao Y,
    6. Yang Z,
    7. Qu J, et al.
    The role of beta-catenin in the initiation and metastasis of ta2 mice spontaneous breast cancer. J Cancer. 2017; 8: 2114–23.
    OpenUrl
  18. 18.
    2. McCubrey JA,
    3. Rakus D,
    4. Gizak A,
    5. Steelman LS,
    6. Abrams SL,
    7. Lertpiriyapong K, et al.
    Effects of mutations in wnt/beta-catenin, hedgehog, notch and pi3k pathways on gsk-3 activity-diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta. 2016; 1863: 2942–76.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Aristizabal-Pachon AF,
    3. Castillo WO.
    Role of gsk3beta in breast cancer susceptibility. Cancer Biomark. 2017; 18: 169–75.
    OpenUrl
  20. 20.↵
    2. Ko HW,
    3. Lee HH,
    4. Huo L,
    5. Xia W,
    6. Yang CC,
    7. Hsu JL, et al.
    Gsk3beta inactivation promotes the oncogenic functions of ezh2 and enhances methylation of h3k27 in human breast cancers. Oncotarget. 2016; 7: 57131–44.
    OpenUrl
  21. 21.↵
    2. Armanious H,
    3. Deschenes J,
    4. Gelebart P,
    5. Ghosh S,
    6. Mackey J,
    7. Lai R.
    Clinical and biological significance of gsk-3beta inactivation in breast cancer-an immunohistochemical study. Hum Pathol. 2010; 41: 1657–63.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Quintayo MA,
    3. Munro AF,
    4. Thomas J,
    5. Kunkler IH,
    6. Jack W,
    7. Kerr GR, et al.
    Gsk3beta and cyclin d1 expression predicts outcome in early breast cancer patients. Breast Cancer Res Treat. 2012; 136: 161–8.
    OpenUrlPubMed
  23. 23.↵
    2. Narni-Mancinelli E,
    3. Vivier E,
    4. Kerdiles YM.
    The 't-cell-ness' of nk cells: Unexpected similarities between nk cells and t cells. Int Immunol. 2011; 23: 427–31.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Brumbaugh KM,
    3. Binstadt BA,
    4. Leibson PJ.
    Signal transduction during nk cell activation: Balancing opposing forces. Curr Top Microbiol Immunol. 1998; 230: 103–22.
    OpenUrlPubMed
  25. 25.↵
    2. Fauriat C,
    3. Long EO,
    4. Ljunggren HG,
    5. Bryceson YT.
    Regulation of human nk-cell cytokine and chemokine production by target cell recognition. Blood. 2010; 115: 2167–76.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. Mincheva-Nilsson L,
    3. Baranov V.
    Cancer exosomes and nkg2d receptor-ligand interactions: Impairing nkg2d-mediated cytotoxicity and anti-tumour immune surveillance. Semin Cancer Biol. 2014; 28: 24–30.
    OpenUrl
  27. 27.↵
    2. Diefenbach A,
    3. Jensen ER,
    4. Jamieson AM,
    5. Raulet DH.
    Rae1 and h60 ligands of the nkg2d receptor stimulate tumour immunity. Nature. 2001; 413: 165–71.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    2. Chang YH,
    3. Connolly J,
    4. Shimasaki N,
    5. Mimura K,
    6. Kono K,
    7. Campana D.
    A chimeric receptor with nkg2d specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013; 73: 1777–86.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Shan M,
    3. Qin J,
    4. Jin F,
    5. Han X,
    6. Guan H,
    7. Li X, et al.
    Autophagy suppresses isoprenaline-induced m2 macrophage polarization via the ros/erk and mtor signaling pathway. Free Radic Biol Med. 2017; 110: 432–43.
    OpenUrl
  30. 30.↵
    2. Brandes RP,
    3. Weissmann N,
    4. Schroder K.
    Nox family nadph oxidases: Molecular mechanisms of activation. Free Radic Biol Med. 2014; 76: 208–26.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Sena LA,
    3. Chandel NS.
    Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012; 48: 158–67.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    2. Selivanov VA,
    3. Votyakova TV,
    4. Pivtoraiko VN,
    5. Zeak J,
    6. Sukhomlin T,
    7. Trucco M, et al.
    Reactive oxygen species production by forward and reverse electron fluxes in the mitochondrial respiratory chain. PLoS Comput Biol. 2011; 7: e1001115.
  33. 33.↵
    2. Zorov DB,
    3. Juhaszova M,
    4. Sollott SJ.
    Mitochondrial reactive oxygen species (ros) and ros-induced ros release. Physiol Rev. 2014; 94: 909–50.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Sabharwal SS,
    3. Schumacker PT.
    Mitochondrial ros in cancer: Initiators, amplifiers or an achilles’ heel? Nat Rev Cancer. 2014; 14: 709–21.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Ralph SJ,
    3. Rodriguez-Enriquez S,
    4. Neuzil J,
    5. Saavedra E,
    6. Moreno-Sanchez R.
    The causes of cancer revisited: "Mitochondrial malignancy" And ros-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med. 2010; 31: 145–70.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    2. Yang Y,
    3. Karakhanova S,
    4. Hartwig W,
    5. D'Haese JG,
    6. Philippov PP,
    7. Werner J, et al.
    Mitochondria and mitochondrial ros in cancer: Novel targets for anticancer therapy. J Cell Physiol. 2016; 231: 2570–81.
    OpenUrl
  37. 37.↵
    2. Mimura K,
    3. Kua LF,
    4. Shimasaki N,
    5. Shiraishi K,
    6. Nakajima S,
    7. Siang LK, et al.
    Upregulation of thioredoxin-1 in activated human nk cells confers increased tolerance to oxidative stress. Cancer Immunol Immunother. 2017; 66: 605–13.
    OpenUrl
  38. 38.↵
    2. Ke M,
    3. Wang H,
    4. Zhou Y,
    5. Li J,
    6. Liu Y,
    7. Zhang M, et al.
    Sep enhanced the antitumor activity of 5-fluorouracil by up-regulating nkg2d/mica and reversed immune suppression via inhibiting ros and caspase-3 in mice. Oncotarget. 2016; 7: 49509–26.
    OpenUrl
  39. 39.↵
    2. Rajesh K,
    3. Iyer A,
    4. Suragani RN,
    5. Ramaiah KV.
    Intersubunit and interprotein interactions of alpha- and beta-subunits of human eif2: Effect of phosphorylation. Biochem Biophys Res Commun. 2008; 374: 336–40.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Sudhakar A,
    3. Ramachandran A,
    4. Ghosh S,
    5. Hasnain SE,
    6. Kaufman RJ,
    7. Ramaiah KV.
    Phosphorylation of serine 51 in initiation factor 2 alpha (eif2 alpha) promotes complex formation between eif2 alpha(p) and eif2b and causes inhibition in the guanine nucleotide exchange activity of eif2b. Biochemistry. 2000; 39: 12929–38.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    2. Cheng Y,
    3. Xia Z,
    4. Han Y,
    5. Rong J.
    Plant natural product formononetin protects rat cardiomyocyte h9c2 cells against oxygen glucose deprivation and reoxygenation via inhibiting ros formation and promoting gsk-3beta phosphorylation. Oxid Med Cell Longev. 2016; 2016: 2060874.
    OpenUrl
  42. 42.↵
    2. Rajesh K,
    3. Krishnamoorthy J,
    4. Kazimierczak U,
    5. Tenkerian C,
    6. Papadakis AI,
    7. Wang S, et al.
    Phosphorylation of the translation initiation factor eif2alpha at serine 51 determines the cell fate decisions of akt in response to oxidative stress. Cell Death Dis. 2015; 6: e1591.
  43. 43.↵
    2. Verma NK,
    3. Fazil MH,
    4. Ong ST,
    5. Chalasani ML,
    6. Low JH,
    7. Kottaiswamy A, et al.
    Lfa-1/icam-1 ligation in human t cells promotes th1 polarization through a gsk3beta signaling-dependent notch pathway. J Immunol. 2016; 197: 108–18.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    2. Eo HJ,
    3. Park GH,
    4. Jeong JB.
    The involvement of cyclin d1 degradation through gsk3beta-mediated threonine-286 phosphorylation-dependent nuclear export in anti-cancer activity of mulberry root bark extracts. Phytomedicine. 2016; 23: 105–13.
    OpenUrl
  45. 45.
    2. Yoeli-Lerner M,
    3. Chin YR,
    4. Hansen CK,
    5. Toker A.
    Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the nfat1 transcription factor. Mol Cancer Res. 2009; 7: 425–32.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    2. Weiss CS,
    3. Ochs MM,
    4. Hagenmueller M,
    5. Streit MR,
    6. Malekar P,
    7. Riffel JH, et al.
    Dyrk2 negatively regulates cardiomyocyte growth by mediating repressor function of gsk-3beta on eif2bepsilon. PLoS One. 2013; 8: e70848.
  47. 47.↵
    2. Hohn A,
    3. Konig J,
    4. Grune T.
    Protein oxidation in aging and the removal of oxidized proteins. J Proteomics. 2013; 92: 132–59.
    OpenUrlCrossRefPubMed
  48. 48.↵
    2. Graff JR,
    3. McNulty AM,
    4. Hanna KR,
    5. Konicek BW,
    6. Lynch RL,
    7. Bailey SN, et al.
    The protein kinase cbeta-selective inhibitor, enzastaurin (ly317615.Hcl), suppresses signaling through the akt pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005; 65: 7462–9.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    2. Hu Y,
    3. Tian ZG,
    4. Zhang C.
    Chimeric antigen receptor (car)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018; 39: 167–76.
    OpenUrl
  50. 50.↵
    2. Aydin E,
    3. Johansson J,
    4. Nazir FH,
    5. Hellstrand K,
    6. Martner A.
    Role of nox2-derived reactive oxygen species in nk cell-mediated control of murine melanoma metastasis. Cancer Immunol Res. 2017; 5: 804–11.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    2. Zhang B,
    3. Liu Z,
    4. Hu X.
    Inhibiting cancer metastasis via targeting napdh oxidase 4. Biochem Pharmacol. 2013; 86: 253–66.
    OpenUrlPubMed
  52. 52.↵
    2. Ugolkov A,
    3. Gaisina I,
    4. Zhang JS,
    5. Billadeau DD,
    6. White K,
    7. Kozikowski A, et al.
    Gsk-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016; 380: 384–92.
    OpenUrl
  53. 53.↵
    2. Acin-Perez R,
    3. Fernandez-Silva P,
    4. Peleato ML,
    5. Perez-Martos A,
    6. Enriquez JA.
    Respiratory active mitochondrial supercomplexes. Mol Cell. 2008; 32: 529–39.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    2. Koit A,
    3. Shevchuk I,
    4. Ounpuu L,
    5. Klepinin A,
    6. Chekulayev V,
    7. Timohhina N, et al.
    Mitochondrial respiration in human colorectal and breast cancer clinical material is regulated differently. Oxid Med Cell Longev. 2017; 2017: 1372640.
    OpenUrl
  55. 55.↵
    2. Rohlenova K,
    3. Sachaphibulkij K,
    4. Stursa J,
    5. Bezawork-Geleta A,
    6. Blecha J,
    7. Endaya B, et al.
    Selective disruption of respiratory supercomplexes as a new strategy to suppress her2(high) breast cancer. Antioxid Redox Signal. 2017; 26: 84–103.
    OpenUrl
  56. 56.↵
    2. Wang X,
    3. Paulin FE,
    4. Campbell LE,
    5. Gomez E,
    6. O'Brien K,
    7. Morrice N, et al.
    Eukaryotic initiation factor 2b: Identification of multiple phosphorylation sites in the epsilon-subunit and their functions in vivo. EMBO J. 2001; 20: 4349–59.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    2. Dholakia JN,
    3. Mueser TC,
    4. Woodley CL,
    5. Parkhurst LJ,
    6. Wahba AJ.
    The association of nadph with the guanine nucleotide exchange factor from rabbit reticulocytes: A role of pyridine dinucleotides in eukaryotic polypeptide chain initiation. Proc Natl Acad Sci U S A. 1986; 83: 6746–50.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    2. Girardi M,
    3. Oppenheim DE,
    4. Steele CR,
    5. Lewis JM,
    6. Glusac E,
    7. Filler R, et al.
    Regulation of cutaneous malignancy by gammadelta t cells. Science. 2001; 294: 605–9.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords